Schrödinger Revises 2025 Software Growth Forecast to 8%-13% Due to Pharma Scale-Up Delays and Emphasis on Operational Efficiency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy SDGR?
Source: SeekingAlpha
Management Overview: CEO Ramy Farid reported a 54% increase in total revenue to $54 million for Q3 2025, driven by strong demand for software and drug discovery solutions, while adjusting software revenue growth guidance to 8%-13% due to delays in pharma scale-up opportunities.
Financial Performance: The company achieved software revenue of $40.9 million and drug discovery revenue of $13.5 million, with a net loss of $33 million. Operating expenses decreased, and cash reserves stood at $401 million as of September 30.
Strategic Focus: Schrödinger is shifting its strategy away from advancing internal discovery programs independently, emphasizing early-stage discovery partnerships and operational efficiency to navigate current market challenges.
Analyst Sentiment: Analysts expressed concerns about customer acquisition and growth visibility, noting a cautious tone from management regarding near-term uncertainties, while maintaining optimism about long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SDGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SDGR
Wall Street analysts forecast SDGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SDGR is 21.83 USD with a low forecast of 18.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 12.940
Low
18.00
Averages
21.83
High
25.00
Current: 12.940
Low
18.00
Averages
21.83
High
25.00
About SDGR
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
Schrodinger Partners with Eli Lilly to Launch AI Drug Design Platform TuneLab
- Collaborative Innovation: Schrodinger's partnership with Eli Lilly integrates Lilly's AI platform TuneLab into its LiveDesign software, enabling biotech companies to directly access this advanced tool, thereby accelerating drug development processes.
- Technological Advantage: By incorporating TuneLab into LiveDesign, chemists can more effectively design compounds and predict drug behavior in the body, enhancing the efficiency and accuracy of drug research and development.
- Market Demand: With the FDA pushing to reduce animal testing, the increasing adoption of AI by drug developers is expected to meet the urgent market demand for faster and more cost-effective drug discovery, making this collaboration timely.
- Client Expansion: Existing LiveDesign clients will gain access to TuneLab in Q1 of this year, while new users will start using it in Q2, which is anticipated to attract more biotech companies and drive diversity and speed in drug development.
See More
Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects
- Market Strength: As of the end of 2025, the U.S. stock market is notably strong, with the S&P 500 reaching all-time highs, reflecting investor confidence amid rising precious metal prices and stable Treasury yields.
- Pinnacle Financial Overview: Pinnacle Financial Partners has a market cap of $7.79 billion and generates $1.89 billion in annual revenue, with earnings and revenue expected to grow significantly over the next three years, despite a low forecasted return on equity of 11.3%.
- M&A Impact: The recent regulatory approval for Pinnacle's merger with Synovus Financial Corp is expected to positively influence future performance, with integration efforts projected to be completed by 2027, enhancing market competitiveness.
- Other Undervalued Stocks: In the U.S. market, companies like Zymeworks, UMB Financial, and Sportradar show significant undervaluation potential, with estimated discounts ranging from 48% to 49%, attracting investor interest.
See More
Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of α-Klotho in vascular health, providing scientific backing for its Klothonova therapy developed in partnership with Singapore's Austrianova, which is expected to enhance market acceptance of the therapy.
- Significant Market Potential: The precision medicine market is projected to grow from $119 billion in 2025 to $471 billion by 2034, and Avant's technological innovations align perfectly with this trend, positioning the company to capture a significant share of the future market.
- Deepened Strategic Collaboration: The exclusive global licensing agreement with Klothea Bio grants Klothonova rights to develop and commercialize Klotho-producing cells, leveraging Austrianova's technology, which is anticipated to accelerate the product's market entry.
- Diversified Investment Strategy: Avant is also collaborating with SGAustria to provide funding over the next eight months for diabetes treatment, demonstrating its strategic intent to expand across multiple therapeutic areas.
See More
Avant Technologies Strengthens Clinical Validation of α-Klotho, Advancing Cell Therapy Progress
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of the 'longevity protein' α-Klotho in vascular health, bolstering the scientific foundation for its joint venture Klothonova with Singapore's Austrianova, advancing cell therapy development.
- Significant Market Potential: As precision medicine expands, the sector is projected to grow from $119 billion in 2025 to $471 billion by 2034, positioning Avant Technologies at the forefront of this transformation, particularly in rare disease treatments.
- Innovative Technology: Klothonova's cell therapy aims to sustainably restore α-Klotho levels using genetically modified human cells, which is expected to revolutionize cardiovascular health and overall longevity, addressing the increasing market demand.
- Strategic Investment: Avant Technologies' joint venture Insulinova with SGAustria aims to develop an efficient diabetes treatment, with initial funding expected in the next eight months to drive innovative solutions for global diabetes patients.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Surge: The global AI medical imaging market is projected to reach $2.57 trillion by 2026, driving the AI drug discovery sector to $1.81 billion, indicating a robust shift towards AI-native diagnostic precision in healthcare.
- Strong Investment Demand: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization and market expansion, marking a pivotal transition from development to revenue generation.
- Economic Value Proposition: VentriPoint is collaborating with Summit Sciences to develop ROI models that demonstrate measurable savings for hospitals through enhanced diagnostic accuracy and resource optimization, thereby strengthening its competitive position.
- Executive Appointment: The appointment of David Swetlow as CFO, with over 15 years of experience in medical technology, is expected to accelerate market adoption and revenue growth, facilitating the execution of the company's commercial strategy.
See More
VentriPoint Diagnostics Accelerates Commercialization of Cardiac Imaging Technology
- Market Potential: The global AI medical imaging market reached $2.57 trillion in 2026, driving the AI drug discovery sector to $1.81 billion, indicating a strong shift towards AI-native diagnostic precision in healthcare.
- Increased Funding: VentriPoint Diagnostics doubled its private placement from $500,000 to $1 million, with the capital allocated for commercialization activities, manufacturing scale-up, and regulatory submissions, facilitating the company's transition from development to revenue generation.
- Economic Value Proof: VentriPoint partnered with Summit Sciences to develop ROI models that demonstrate measurable returns for hospitals through process improvements and resource optimization, emphasizing the economic rationale of their technology.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, leveraging his extensive management experience in medical technology to accelerate market adoption and drive revenue growth.
See More
Schrodinger Partners with Eli Lilly to Launch AI Drug Design Platform TuneLab
- Collaborative Innovation: Schrodinger's partnership with Eli Lilly integrates Lilly's AI platform TuneLab into its LiveDesign software, enabling biotech companies to directly access this advanced tool, thereby accelerating drug development processes.
- Technological Advantage: By incorporating TuneLab into LiveDesign, chemists can more effectively design compounds and predict drug behavior in the body, enhancing the efficiency and accuracy of drug research and development.
- Market Demand: With the FDA pushing to reduce animal testing, the increasing adoption of AI by drug developers is expected to meet the urgent market demand for faster and more cost-effective drug discovery, making this collaboration timely.
- Client Expansion: Existing LiveDesign clients will gain access to TuneLab in Q1 of this year, while new users will start using it in Q2, which is anticipated to attract more biotech companies and drive diversity and speed in drug development.
See More
Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects
- Market Strength: As of the end of 2025, the U.S. stock market is notably strong, with the S&P 500 reaching all-time highs, reflecting investor confidence amid rising precious metal prices and stable Treasury yields.
- Pinnacle Financial Overview: Pinnacle Financial Partners has a market cap of $7.79 billion and generates $1.89 billion in annual revenue, with earnings and revenue expected to grow significantly over the next three years, despite a low forecasted return on equity of 11.3%.
- M&A Impact: The recent regulatory approval for Pinnacle's merger with Synovus Financial Corp is expected to positively influence future performance, with integration efforts projected to be completed by 2027, enhancing market competitiveness.
- Other Undervalued Stocks: In the U.S. market, companies like Zymeworks, UMB Financial, and Sportradar show significant undervaluation potential, with estimated discounts ranging from 48% to 49%, attracting investor interest.
See More
Avant Technologies Strengthens Clinical Validation for α-Klotho Therapy
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of α-Klotho in vascular health, providing scientific backing for its Klothonova therapy developed in partnership with Singapore's Austrianova, which is expected to enhance market acceptance of the therapy.
- Significant Market Potential: The precision medicine market is projected to grow from $119 billion in 2025 to $471 billion by 2034, and Avant's technological innovations align perfectly with this trend, positioning the company to capture a significant share of the future market.
- Deepened Strategic Collaboration: The exclusive global licensing agreement with Klothea Bio grants Klothonova rights to develop and commercialize Klotho-producing cells, leveraging Austrianova's technology, which is anticipated to accelerate the product's market entry.
- Diversified Investment Strategy: Avant is also collaborating with SGAustria to provide funding over the next eight months for diabetes treatment, demonstrating its strategic intent to expand across multiple therapeutic areas.
See More
Avant Technologies Strengthens Clinical Validation of α-Klotho, Advancing Cell Therapy Progress
- Strengthened Clinical Validation: Avant Technologies announced that a new study from the Mayo Clinic reinforces the critical role of the 'longevity protein' α-Klotho in vascular health, bolstering the scientific foundation for its joint venture Klothonova with Singapore's Austrianova, advancing cell therapy development.
- Significant Market Potential: As precision medicine expands, the sector is projected to grow from $119 billion in 2025 to $471 billion by 2034, positioning Avant Technologies at the forefront of this transformation, particularly in rare disease treatments.
- Innovative Technology: Klothonova's cell therapy aims to sustainably restore α-Klotho levels using genetically modified human cells, which is expected to revolutionize cardiovascular health and overall longevity, addressing the increasing market demand.
- Strategic Investment: Avant Technologies' joint venture Insulinova with SGAustria aims to develop an efficient diabetes treatment, with initial funding expected in the next eight months to drive innovative solutions for global diabetes patients.
See More
